23.01
+0.02(+0.09%)
Currency In USD
Address
131 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America
Phone
650 443 7400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
45
First IPO Date
February 08, 2019
| Name | Title | Pay | Year Born |
| Ms. Julie M. Eastland M.B.A. | Pres, Chief Executive Officer, Sec. & Director | 910,774 | 1964 |
| Dr. Luke N. Walker M.D. | Chief Medical Officer | 424,434 | 1972 |
| Ms. Georgia L. Erbez | Consultant | 484,898 | 1967 |
| Dr. Natalie R. Sacks M.D. | Consultant | 751,791 | 1965 |
| Ms. Wendy Chang | Senior Vice President of HR | 0 | N/A |
| Dr. Chatan Charan Ph.D. | Senior Vice President of Product Devel., Technical & Manufacturing Operations | 0 | N/A |
| Dr. Holger Wesche Ph.D. | Chief Scientific Officer | 0 | 1968 |
| Ms. Rachael Lester | Senior Vice President of Bus. Devel. & Corporation Strategy | 0 | N/A |
| Dr. Banmeet Anand Ph.D. | Senior Vice President of Translational Medicine | 0 | N/A |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
